Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Monday, October 12, 2026

⚡ Executive Takeaway

Merck ran the experiment every retina watcher wanted: a genuinely new mechanism, head to head against the drug that built the field, at pivotal scale. The statistics came back friendly and the medicine did not. Remigromig's noninferiority p values will read as success in a database; the gap between +9.1 and +11.8 letters, next to a proliferative retinopathy rate several times the comparator's, reads differently to a retina specialist choosing a first injection. And the number that decides this program is in neither column, because a Wnt agonist only matters commercially if it eventually buys fewer injections, and year one dosed both arms on the same monthly schedule. The verdict arrives with year two's personalized intervals, not year one's letters.

That is this week's through line: the incumbent's bar. Nothing this weekend was measured against placebo or against zero. New drugs were measured against ranibizumab, intravenous foscarnet, and an existing olanzapine label; new issues were measured against their own offer prices; a next generation diagnostic was measured against its own approved predecessor. Starting Tuesday, Q3 earnings turn the same lens on the incumbents themselves. Clearing your own endpoint is table stakes now. The week belongs to whoever clears the thing that already works.

🔬 The BRUNELLO Verdict

Remigromig met its endpoint and lost the comparison. MRK | RHHBY

Merck's full one year BRUNELLO data, presented Saturday at AAO 2026, showed both doses of the Wnt pathway trispecific meeting noninferiority against ranibizumab in 984 patients with diabetic macular edema: +9.1 and +8.7 letters versus +11.8 for ranibizumab, with no secondary endpoint showing superiority, per Merck's release. The September topline had withheld the safety rates. They arrived Saturday: PDR related adverse events of 6.7% and 6.1% versus 0.9%, and adverse event discontinuations of 4.9% and 4.5% versus 0.9%. Merck calls the PDR cases generally manageable and says the data will be discussed with regulators, with no filing timeline; BAROLO, the second pivotal, continues. Monday is the first session with the full table in the price. The same meeting carried Roche's one year vamikibart data in uveitic macular edema, released without numbers: a numerically higher proportion of treated patients gained vision, and the FDA decision is expected by July 2027, per the company.

💊 The FDA's Friday

Three approvals in one day, each one aimed at a different incumbent. RHHBY | TEVA | Asahi Kasei

The agency approved Tecentriq with chemotherapy for adjuvant stage III dMMR colon cancer on ATOMIC's 50% reduction in recurrence or death risk (36 month disease free survival 86% versus 76% in 712 patients, per Roche), the first checkpoint inhibitor in that curative intent setting and a direct raise on universal mismatch repair testing of resected colon cancers. It approved Teva's Weltruza, the first once monthly subcutaneous olanzapine for schizophrenia, whose label per Teva requires no loading dose, no oral supplementation and no post injection monitoring, deleting the observation burden that has confined long acting olanzapine to a niche. And Friday evening it approved Asahi Kasei's Hovilpri (pritelivir) for mucocutaneous HSV lesions refractory to standard antivirals in immunocompromised adults: 63% complete healing by Day 28 versus 34% on investigator's choice including intravenous foscarnet, with discontinuations of 2% versus 20%, per the release. An oral tablet replacing an inpatient IV with that gap is a pharmacoeconomic argument that writes itself.

💰 The Capital Cycle Closes Its Loop

Cash cleared, and nobody paid a premium for new paper. PCVX | SYRE | TRXB | RTSN

Vaxcyte's concurrent offerings closed Friday with both greenshoes exercised in full within about a day of pricing, netting roughly $1.1 billion combined, per the 8-K (combined figure our arithmetic), and PCVX rose 9.8% to 71.38 on the day the cash banked (our arithmetic from settled closes). Spyre's $350 million offering closed October 7 per its counsel Ropes & Gray, with the company's own closing release still unposted as of Sunday night, our search scope; SYRE rose 7.2% to 85.69, back 0.8% above the offer. The two debuts told the other half of the story: TRexBio settled its first session exactly at the $14.00 offer, and Retension, which priced an upsized $45.0 million IPO at $12.00 per its release, closed its debut at $10.53, 12.2% below offer (our arithmetic). The window is open and unsentimental: completed deals get rewarded, new paper clears at face value or below.

⏰ Monday Morning Binaries

Two toplines land at 8:30 am ET, and one of them tests a brand new drug class. MIRM | TRAX

Mirum announced Sunday evening it will share topline results from EXPAND, its Phase 3 of Livmarli in ultra rare cholestatic liver diseases, on a Monday 8:30 am ET call; the stock had already risen 5.7% Friday (our arithmetic), before the announcement and without any disclosure explaining the move. The same morning, First Tracks Biotherapeutics reports Cohort 1 of its Phase 1b gluten challenge study of ANB033, a CD122 antagonist, in celiac disease. That readout is bigger than the company: argenx's FB102 gave anti CD122 its first celiac win on October 8, and Monday brings the mechanism's second test within a week, from the AnaptysBio spinoff that launched in April with about $180 million and runway into Q2 2028, per its releases. Neither outcome was public at press time. We grade both in Tuesday's edition.

🩺 Diagnostics

Freenome put its next generation numbers on the ACG podium, and the category's whole argument runs through one of them. FRNM | ABT

Freenome's updated SimpleScreen CRC blood test earned a late breaking oral presentation Wednesday at ACG 2026: sensitivity for advanced precancerous lesions of 18.2% versus 13.7% for the approved first generation, high grade dysplasia detection of 41.9% versus 30.5%, cancer sensitivity holding at 80.4%, and specificity of 90%, figures from the company's July topline release now headed for the podium. The first generation launched in late September through Abbott, which holds exclusive US commercialization, and a $70 million milestone rides on FDA approval of the next generation version plus technology transfer, per the July release. Blood based screening wins on adherence; precancer sensitivity is what it concedes to colonoscopy and stool DNA. Every point recovered there shrinks the strongest argument against the category.

🧪 Rare Disease Evidence

BridgeBio spent the weekend arguing against incumbents on two fronts. BBIO

At ASBMR, BridgeBio presented added Phase 3 CALIBRATE evidence for encaleret in autosomal dominant hypocalcemia type 1: 91% versus 0% of participants reaching at least the lower limit of normal parathyroid hormone at 24 weeks against conventional therapy, with the FDA application now under Priority Review with a May 8, 2027 target action date and the first patient dosed in RECLAIM-HP in chronic hypoparathyroidism, per the company's release as carried by StockTitan. The CALIBRATE topline itself dates to last October; this is congress evidence, not a new readout. At HFSA, an independent EHR study of 2,684 ATTR-CM patients associated acoramidis with an 18% lower risk of clinical worsening versus tafamidis and roughly 27% fewer cardiovascular and heart failure hospitalizations, with death alone not significantly different and short follow up flagged, per the release as carried by StockTitan. Real world superiority claims against the entrenched incumbent are now the front line of the ATTR-CM share fight.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review

The weekend handed every new entrant the same examiner: the thing that already works. Monday hands the test to Mirum and First Tracks before the opening bell, and to the first Q3 earnings decks on Tuesday. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →